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DNA METHYLTRANSFERASE 3A CHARACTERIZATION IN CLONAL 
HEMATOPOIESIS, AGING, AND ACUTE MYELOID LEUKEMIA 
MICHAEL WINIK 
ABSTRACT 
The expected growth of the older adult population in the United States over the 
next several decades will have an unprecedented impact on the health care system. 
Research has shown that age is the greatest risk factor for developing cancer and certain 
hematological malignances. Insights on acute myeloid leukemia have suggested that 
premalignant somatic mutations in stem cells are responsible for age associated medical 
conditions. Persistence of preleukemic clones and the risk of relapse is linked with an 
abnormal DNA methyltransferase 3A (DNMT3A) gene especially in the R882H region 
which may lead to a phenomenon known as clonal hematopoiesis. The DNMT3A gene 
provides instructions for making an enzyme that establishes DNA methylation patterns 
and is believed to form the initial mutation in acute myeloid leukemia. Because of the 
significance of DNMT3A mutations in the pathogenesis of leukemias and clonal 
hematopoiesis with respect to the geriatric population, the goal of the thesis was to 
generate DNMT3A proteins for future research via a bacterial expression vector. 
Wildtype and dominant negative DNMT3A proteins were not successfully generated, but 
the study is still an ongoing process. The overview of the entire long term study is to 
focus on the mechanism insight on DNMT3A activity and its contribution to acute 
myeloid leukemia development.  
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1.1 Overview  
Leukemia is a complex disease, but a path forward to potentially cure it is 
revealed with a surprising connection between hematological malignancies and the clonal 
hematopoietic process associated with age (Steensma 2018). Alterations in cellular genes 
- which accumulate over time - are the main drivers in cancer (Risques & Kennedy, 
2018). The acquisition of multiple mutations in oncogenes and tumor suppressor genes 
alter cellular division. Mutations in epigenetic modifying genes such as DNMT3A and 
TET2 are age related and partially responsible for clonal hematopoiesis of indeterminate 
potential which is link to acute myeloid leukemia (AML) (Buscarlet et al., 2017). Since 
the geriatric population has accumulated more DNA errors over a period of time, the 
likelihood of a benign clonal hematopoietic stem cell turning cancerous increases 
exponentially, specifically in hematological systems (López-Otín et al., 2013).  
There is a convergence of concepts related to acute myeloid leukemia. Not only is 
it an age related disease, but AML is a notable exception to most cancers as it possesses 
relatively few mutations across the genome and has unique epigenetic signatures 
(DiNardo & Cortes, 2016). Because of certain defining features of AML, the nature of 
the disease forms the basis of cancer research and clonal hematopoiesis. A thorough 
comprehension of AML requires familiarity of blood formation and leukemia 
classification with an emphasis to the geriatric population. In addition, knowledge of 
clonal hematopoiesis of indeterminate potential along with a brief background in cancer 
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and epigenetics is helpful to better characterize the complexities of AML. Because the 
thesis is rather large in scope, the introduction is organized into sections. 
1.2 Clonal Hematopoiesis 
Clonal hematopoiesis of indeterminate potential (CHIP) is a syndrome primarily 
observed in the elderly (Park & Bejar, 2018). It is an age-related phenomenon in which 
hematopoietic progenitors contribute to the creation of a genetically diverse 
subpopulation of blood cells (Jaiswal et al., 2014). Because of the evolving nature 
associated with clonal hematopoiesis, it is linked to an increased risk of cancer and 
cardiovascular disease (Argüelles et al., 2019). Those with CHIP have commonly 
detectable variants in epigenetic modifying genes such as DNMT3A and TET2 
(Buscarlet et al., 2017). However, CHIP is fairly benign (Park & Bejar, 2018). The 
clinical implications of CHIP are not well understood as it has a low association to 
malignant diseases (Jaiswal et al., 2014). Although it is straightforward to screen those 
for CHIP, therapeutic interventions are absent. Previous research about CHIP suggest it is 
a proinflammatory marker and a potential diagnostic indicator to certain illnesses 
(Jaiswal & Libby, 2019).  
Normal hematopoiesis in adults is the result of a collective contribution of blood 
cell production to maintain steady state levels in the peripheral circulation. In a healthy 
individual, approximately 1011-1012 new blood cells are formed daily from hematopoietic 
stem cells (HSC) (Bouhassira & Vyas, 2015). These HSC usually contribute equally to 
blood cell production, yet in an abnormal state one HSC gives rise to an outsized 
proportion of blood cells. For instance, a single cell may birth > 10 percent of blood cell 
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production (Bouhassira & Vyas, 2015). The expansion of one lineage of cells, or a clone, 
at a scale disproportionately greater than other clones is known as clonal hematopoiesis 
(CH) (Bowman et al., 2018). It has a low risk factor for developing a hematologic 
malignancy (see Figure 1) (Sano et al., 2018). However, CH is characteristic of 
leukemias and the prevalence of both increase with age (Bowman et al., 2018). The belief 
is that over the human life span, somatic DNA mutations accumulate in healthy tissues 
(Steensma 2018). Although most mutations are inconsequential, some give a relative 
fitness advantage on a single stem cell and its offspring (Steensma & Ebert, 2019). 
 
Figure 1: Clonal Hematopoiesis – A Pathway to Cancer. Clonal hematopoiesis 
increases the risk of hematological malignancy, but the probability is low. Individuals 
with clonal hematopoiesis have a 5% chance of developing leukemia. (Adapted from 
Jaiswal et al., 2014) 
  
Clonal hematopoiesis has led to a whole new field of medicine for the elderly. 
Large population studies have identified that CH gradually increases with age (Park & 
Bejar, 2018). Detectable somatic mutations were rare in individuals younger than 40 
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years of age but became more frequent with each decade of life thereafter (Risques & 
Kennedy, 2018). Among individuals greater than 70 years of age, it is estimated that 
9.5% of them have variants in genes linked to clonal hematopoiesis (Jaiswal et al., 2014). 
Furthermore, individuals with CHIP tend to progress to adverse outcomes at a rate of 
about 0.5 to 1% per year (Jaiswal et al., 2014). Retrospective and prospective cohort 
studies of 60 – 70 year old adults suggest that CH is relevant for cardiac disease in the 
elderly with a 4 – fold higher risk of myocardial infarction (Fuster & Walsh, 2018). 
Nonetheless, the amount of clonal hematopoiesis (VAF %) required to increase the risk 
of age-related diseases is not known. Moreover, who is at risk and how does CH evolve?  
 
CANCER 
1.31 Cancer Overview  
Major advances have been made unraveling the etiologies of numerous cancers. 
Yet the precise cause(s) of cancer remain elusive (Blackadar 2016). Percivall Pott was the 
first scientist to demonstrate that cancer may be caused by an environmental carcinogen 
(Benmoussa et al., 2019). However, American Nobel Prize winning Francis Peyton Rous 
suggested in the 1960s that cancer was the result of a virial transmission (Kumar & 
Murphy, 2013). These theories are accurate, but incomplete. Ten years later, the term 
proto-oncogene was back in the scientific spotlight (Kathuria et al., 2010). It was 
believed that certain stressors on DNA active endogenous genes have the potential to 
cause cancer (Macheret & Halazonetis, 2015). Although these theories help characterize 
the nature of cancer, they are helpless in explaining even the simplest inquiries of the 
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disease. Who gets cancer and why? How come it is challenging to treat despite 
chemotherapeutic medications? What is the precise etiology of cancer? Recent CHIP 
research may prove useful in elucidating these frequent and important questions, 
especially in the elderly. 
The frontier of cancer research is evolving towards analyzing the precursor 
conditions leading to the disease (Wacholder 2013). The cure for cancer - as indicated by 
Siddhartha Mukherjee in his Pulitzer Prize winning book The Emperor of All Maladies: A 
Biography of Cancer - begins with its prevention. How can we cure a disease with a 
clonal evolving nature? It commences with analyzing the cells and environment that 
precipitate the trigger of cancer (Wacholder 2013). However, the knowledge to retrace 
and map these events leading to pathology are murky. Current studies suggest that the 
architecture of cancer begins with an early indolent pathological state such as CHIP 
(Steensma 2018). Clonal hematopoiesis may help identify molecular cancer drivers that 
contribute a growth advantage to certain stem cells. Nonetheless, individuals rarely 
experience symptoms of CHIP because these mutations are found within normal 
hematopoietic cells (Genovese et al., 2014). Nevertheless, as one ages, he or she develops 
and acquires more mutations (see Figure 2), thus illuminating the age related component 
of cancer (Milholland et al., 2015).   
 




Figure 2: Prevalence of Somatic Mutations as a Function of Age. The frequency of 
mutations increases with age in the general population. (Adapted from Jaiswal et al., 
2014) 
 
1.32 Genetics of Cancer  
Cancer is a multistep disease as single mutations are not sufficient to produce 
illness (Jackson & Loeb, 1998). The average cancer cell genome has hundreds and 
sometimes thousands of mutations (Anandakrishnan et al., 2019). Amongst all those 
mutations found, approximately 5 – 20 are in oncogenes and tumor suppressor genes 
(Martincorena 2017). Hence, it is likely that only a few mutations (driver genes) are 
participating in the development of cancer. The remainder are simply known as passenger 
mutations or silent mutations as they occur during the lifetime of the disease (Stratton et 
al., 2009). Hence, these mutations are carried with the driver genes and are not 
contributing to the cancer phenotype. The analysis of the cancer genome is very 
complicated as it difficult to distinguish between a passenger or driver mutation (Pon & 
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Marra, 2015). Fortunately, because of modern technological advancement, scientists are 
better able to locate and analyze important cancer genes (Stratton et al., 2009).  
An oncogene is a gene that when mutated has the potential to cause cancer 
(Stratton et al., 2009). These genes are responsible for cell growth and proliferation – the 
essence of a tumor. Most normal cells will undergo a controlled program cell death 
known as apoptosis (Shortt & Johnstone, 2012). There are a few mechanisms that switch 
normal cells into cancer including but not limited to replication errors and chromosomal 
segregation defects. Mutations seen in oncogenes are typically dominant and gain of 
function (Stratton et al., 2009). Furthermore, they increase proliferation and decrease cell 
death. The first of these oncogenes was observed by Francis Peyton Rous in oncogenic 
viruses such as HPV (Kumar & Murphy, 2013). When uncorrupted, oncogenes are vital 
to normal cell division processes and thus are evolutionarily advantageous (Shortt & 
Johnstone, 2012; DeGregori 2014). However, in the context of cancer these genes 
become altered (Stratton et al., 2009).  
  Tumor suppressor genes – “antioncogenes” – are important for cancer regulation. 
They are responsible for slowing down cell division and repairing errors in DNA 
transcription (Stratton et al., 2009). These genes as such are inactivated during cancer in 
contrast to oncogenes. In addition, tumor suppressor genes are recessive (Payne & Kemp, 
2005). Hence, a mutation is needed on both pairs of homogenous chromosomes to cause 
cancer (Knudson hypothesis) or via a chromosomal non-disjunction with the mutant copy 
(Paige 2003). Most tumor suppressor genes are acquired spontaneously and are not 
inherited (Stratton et al., 2009). However, those with familial cancer syndromes have a 
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predisposition to certain cancers due to a family history of inherited abnormalities of 
tumor suppressor genes. For example, those with a TP53 gene mutation are acquired and 
represent deficits in half of all human cancers (Rivlin et al., 2011).   
1.33 Conventional and New Therapeutic Approaches  
 The most effective and oldest form of cancer therapy is surgery (DeVita & Chu, 
2008). If the tumor and the nearby tissue are removed before metastasis, the patient is 
generally cured (Tohme et al., 2017). Depending on the location and grade of the tumor, 
radiation is a popular choice of treatment. Ionizing radiation beams focus on cancer cells 
thus damaging them in the process (DeVita & Chu, 2008). The next most common 
technique to treat cancer is chemotherapy (DeVita & Chu, 2008). When the cancer has 
spread, radiation is ineffective because the cancer cells are not localized. Chemotherapy 
drugs are able to diffuse throughout the body systems and can eliminate the cancer cells 
(Dewhirst & Secomb, 2017). Radiation and chemotherapy both function by inducing 
DNA damage or inhibiting mitosis (Arruebo et al., 2011). While these agents are 
effective in causing tumor death, some normal cells are sensitive to radiation and 
chemotherapy (Baskar et al., 2012). Hence, unwanted side effects to treatment are 
extremely common in cancer patients. In addition, many cancers still persist despite 
medical treatment. Although radiation and chemotherapy may shrink the tumor, some 
cancer cells remain resistant and potentially metastasize (DeVita & Chu, 2008).  
 There are several new approaches to cancer therapy. These are anticancer agents 
targeted and specific to a certain subtype of the disease (Pucci et al., 2019). Some 
targeted therapies block the action of certain enzymes that carries a mutation involved in 
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tumor growth (Arruebo et al., 2011). Another form of targeted therapy includes 
immunotherapy, particularly monoclonal antibodies. Small-molecule drugs such as 
angiogenesis inhibitors keep tissue around the tumor from forming blood vessels (Pucci 
et al., 2019). Examples of targeted therapy include breast, colorectal, and lung cancer 
(Tsimberidou 2015). Although targeted therapy is preferred, it is often not a viable 
treatment. Researchers are studying many new drugs while personalized medicine 
specifically for cancer treatments is imminent (Krzyszczyk et al., 2018).   
 
GERIATRIC MEDICINE 
1.41 Overview  
Geriatric medicine is one of the fastest growing specialties in healthcare 
(Brummel & Ferrante, 2017). As the worldwide population ages, the healthcare 
community and economy will face significant challenges to meet the needs of the elderly 
(Knickman & Snell, 2002). According to the United States Census Bureau website, the 
number of Americans > 65 years of age is expected to double from 53 million currently 
to 95 million in 2060 (Vincent & Velkoff, 2010). In addition, An Aging World, a Census 
Bureau report co-authored by Wan He, expects that by 2050 those aged 65 and over will 
significantly outnumber children driven by the large baby boom generation. Because 
aging is associated with decrease health, chronic conditions such as heart disease, stroke, 
and cancer will become exponentially more prevalent in the next several decades 
(Brunilda et al., 2020). Simultaneously, healthcare professionals will need to address 
comorbidities instead of single diseases (Karlamangla et al., 2007). Managing these 
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conditions will increase the financial demands of the healthcare system (Cortaredona & 
Ventelou, 2017). 
 The health challenges faced by the elderly are more difficult than younger adults. 
The elderly are subject to polypharmacy and multiple medical disorders (Maher et al., 
2013; Karlamangla et al., 2007). The Centers for Disease Control (CDC) and the 
National Counsel of Aging at the NIH approximate that of those 65 years of age or older, 
80% of them have at least one chronic disease and 77% have at least two ailments 
(National Counsel of Aging Factsheet). In addition, 60% of all cancers and 70% of cancer 
related deaths occur with the elderly (Cinar & Tas, 2015). The International Cancer 
Research Institute estimates an increase of 22 million cases of cancer within the next two 
decades. Currently, these chronic diseases account for three quarters of the United States 
healthcare (Barrett et al., 2016). There is increasing data to suggest that toxicity to cancer 
treatment is more severe to the elderly (Repetto 2003). Frailty syndrome, which carries 
an increased risk for poor outcomes, is considered a culprit of these current statistics 
(Xue 2012). A decline in health and function is seen in older adults (Brunilda et al., 
2020).   
 Although aging is a risk factor for developing cancer, it is a natural part of life 
(Brunilda et al., 2020). Because of the improvements in health and medicine, the 
challenges of an aging population are becoming an issue (Christensen et al., 2009). As 
one ages, there is increasing genomic instability, telomere attrition, and epigenetic 
alterations (López-Otín et al., 2013). DNA replication errors continue to accumulate in 
the aging process as these mistakes are passed down from each generation of cells 
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(Milholland et al., 2015). In addition, telomeres – which play a central role in cell fate – 
become dysfunctional leading to cancer (Gunes et al., 2018). Inadequate telomere repair 
is associated also with a variety of diseases including several hematological malignancies 
like acute myeloid leukemia (Kishtagari & Watts, 2017). Telomere maintenance has an 
important function for pluripotent and multipotent stem cells with regards to clonal 
hematopoiesis. The expansion of these cells is halted with telomere shortening and 




1.51 Overview  
 
Interest in the field of epigenetics has increased rapidly with the term becoming 
more identifiable in the scientific literature and even the main stream media. Different 
descriptions have been ascribed to the term over the years, thus blurring the definition. 
British embryologist Conrad Waddington coined the term epigenetics in the 1940s to 
categorize the integrated knowledge of genes and genetics (Deans & Maggert, 2015). His 
definition was used to denote the poorly understood mechanisms by which a fertilized 
ovum develops into a mature, complex organism. Epigenetics to Waddington was not 
very different from embryology and more importantly had no molecular insights to 
consider (Deans & Maggert, 2015). However, with the benefits of modern insight and 
increased knowledge of gene expression, the definition of epigenetics has been refined 
and narrowed.  
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The term epi is derived from Greek prefix meaning upon or above. Up-to-date 
knowledge of epigenetics refers to the “post-genomic” era. In spite of the completion of 
the Human Genome Project – which successfully sequenced every gene in the human 
organism – gene expression control is not adequately explained without an epigenetic 
perspective. Every cell in the organism contains the same genetic code, yet cells in 
different tissues have unique structure and functions (Rasmussen 2003). Epigenetics 
seeks to understand how this happens. It focuses on the surrounding structure of DNA 
that control the expression and heritability of genes (Deans & Maggert, 2015). Chemical 
tags such as covalent modifications allow certain genes to be turned on or off (Kanherkar 
et al., 2014). These epigenetic modifications may bring lasting changes to gene 
expression without altering the underlying DNA sequence and therefore the genetic code 
(Handy et al., 2011).  
1.52 Molecular Basis of Epigenetics  
 The molecular basis of epigenetics is a complex phenomenon that involves the 
activation or repression of certain genes without altering the underlying genetic sequence 
of DNA. (Plass et al., 2008). The machinery involved in these modifications enables 
differentiated cells to have their own separate structure and function (Rasmussen 2003). 
Most epigenetic changes occur only during mitosis, while some are transmitted to the 
offspring of the organism through a process called transgenerational epigenetic 
inheritance (Heard & Martiensenn, 2014). Specific epigenetic processes include 
bookmarking, imprinting, paramutation, gene silencing, and chromosome X-inactivation 
(Moosavi & Ardekani, 2016; Handy et al., 2011). These phenomena often define and 
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dictate the faith of the cell as well as the organism. A wide range of molecular biological 
techniques such as chromatin immunoprecipitation and bisulfite sequencing are 
employed to decipher these mechanisms. The molecular targets of epigenetic processes 
include DNA, histones, miRNAs, sRNAs, and prions (Choudhuri et al., 2010).  
1.53 Epigenetic Regulators in AML – DNMT3A and TET2 
 DNA (cytosine-5)-methyltransferase 3A (DNMT3A) is an enzyme that is 
involved in de novo DNA methylation. It is part of a family of DNA methyltransferase 
enzymes that include DNMT1 and DNM3B (Yang et al., 2015). The protein structure of 
DNMT3A comprises of three highly conserved domains: the Pro-Trp-Trp-Pro (PWWP) 
domain, the ATRX-DNMT3-DNMT3L (ADD) domain, and the catalytic 
methyltransferase domain (Yang et al., 2015). Animal studies in mice have revealed the 
biological significance of DNA methylation as it is shown that targeted deletion of all 
DNMT enzymes results in lethality (Plass et al., 2008). Moreover, DNMT3A-/- mice 
have an increase in self-renewal cell division (clonal hematopoiesis) – a hallmark of 
cancer (Mayle et al., 2015). Although these mutations are seen in cancer, they are most 
commonly detected in acute myeloid leukemia and are linked to a poor prognosis along 
with decreased overall survival (Sun et al., 2018). Because DNMT3A mutations produce 
immortalized stem cells, they are sometimes associated with positive health outcomes in 
the elderly (Jeong et al., 2017). Research has suggested that these mutations might not 
solely lead to direct leukemic transformation, but rather form the premalignant state for 
hematological malignancy (Sun et al., 2018; Corces-Zimmerman et al., 2014).  
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 Tet methylcytosine dioxygenase 2 (TET2) is a gene that catalyzes the conversion 
of methylcytosine to 5-hydroxymethylcytosine with the cofactor molecule α-
ketoglutarate (α-KG) (Solary et al., 2014). The TET2 protein is involved in regulating the 
process of transcription and DNA demethylation (Feng et al., 2019). Although the 
encoded protein is ubiquitous throughout the human body, research suggests that it has a 
specific function in the formation of blood cells from hematopoietic stem cells (Solary et 
al., 2014). It appears that the protein acts as a tumor suppressor, thus regulating cells 
during division and replication. Defects in the gene are associated with several 
myeloproliferative disorders and acute myeloid leukemias (Feng et al., 2019). TET2 
inactivation in mice has revealed hematopoietic defects. Similar to the DNMT3A 
mutation, TET2 protein misfolding has a unfavorable prognostic indication (Feng et al., 
2019). Published data from Wang et al. (2019) in the journal BMC Cancer have indicated 
that AML patients will on average have a TET mutation varying from 6.05 to 27.36% 




1.61 Leukemia and Hematopoiesis  
 
The study of leukemia has always been at the forefront of cancer research. It is a 
disease of early blood-forming cells and originates in the bone marrow. Leukemic cells 
may crowd out or suppress the development of normal cells leaving the individual prone 
to infection (Duarte et al., 2018). The rate of progression (acute vs chronic) and specific 
blood cell affected (myeloid vs lymphoid) are different with each type of leukemia 
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(Mackey & Klemm, 2000). Healthcare professionals have therefore categorized leukemia 
into four broad categories: acute lymphocytic, acute myeloid, chronic lymphocytic, and 
chronic myeloid (Mackey & Klemm, 2000). In total, the UPMC Hillman Cancer center 
website states that leukemia affects 45,000 people in the United States each year 
(“Leukemia,” 2016). The NIH website estimates that as of 2016, over 400,000 
individuals are living with some form of the disease (“Cancer Stat Facts: Leukemia,” 
2016). Because of the heterogeneity of the cancer, no two patients are alike, and the 
treatment and response can vary greatly (Li et al., 2016). Therefore, it is crucial for 
scientists to understand the pathogenesis of the disease and analyze each subtype of 
leukemia separately.   
 Hematopoiesis serves as a key model system to understand the basics of 
leukemia. The term simply means the process by which the body manufactures blood 
cells. All these cells develop from hematopoietic stem cells (HSCs) that can produce any 
other blood component (Gulati et al., 1988). Each of these components fall into one of 
three broad categories: erythrocytes, leukocytes, and thrombocytes. Red blood cells carry 
oxygen to tissues throughout the body, while white blood cells help fight infection and 
platelets form blood clots that control bleeding (Kuhn et al., 2017; King et al., 2018). The 
process of hematopoiesis initiates with an unspecialized stem cell in the bone marrow 
(Gulati et al., 1988). These stem cells transform into common lymphoid and myeloid 
progenitors to create two distinct pathways (see Figure 3). The common lymphoid 
progenitors further differentiate into separate lymphoblasts that help form the immune 
system. Lineage of the common myeloid progenitors separate into red blood cells, 
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platelets, or one of several types of white blood cells (Kondo 2010). Because the disease 
can originate in either lymphoid or myeloid lineage, the various forms of leukemia are 
grouped specifically on the type of white blood cell affected and the rate at which 
symptoms develop (Mackey & Klemm, 2000). 
 
 
Figure 3: Diagram of Hematopoietic Hierarchy. Development of different blood and 
immune cells originating from a common hematopoietic stem cell (HSC). (Adapted from 
Nemeth & Bodine, 2007) 
 
The majority of blood cells mature in the red spongy tissue of the bone marrow 
and then move into the peripheral vessels (Kuhn et al., 2017). In a leukemic individual, 
there is an abnormal amount of white blood cells that overtake the bone marrow. These 
overly abundant cells are not functioning as properly and are consuming more energy 
than their normal counterparts (Mackey & Klemm, 2000). Hence, the bone marrow is not 
able to produce enough of the normal blood cells. When the leukemic cells have no more 
space in the bone marrow, they eventually leak into the bloodstream (Kuhn et al., 2017). 
These events create a host of disorders such as anemia, thrombocytopenia, and 
leukopenia (Jalaeikhoo et al., 2017). Since leukemic cells are able to spread throughout 
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the body, the digestive tract, kidneys, lungs, heart are also affected (Luciano & Brewster, 
2014; Ebert & Hagspiel, 2012). A common mechanism to diagnose leukemia is through a 
routine blood test and bone marrow biopsy (Béné et al., 2015).  
1.62 Four Main Types of Leukemia    
Leukemia is classified by the type of white blood cell affected and by how 
quickly the disease progresses (Mackey & Klemm, 2000). Uncontrolled proliferation of 
partially developed blast cells is a defining feature of acute leukemia while large amounts 
of morphologically mature, but functionally incompetent hematopoietic cells are 
recognized as chronic leukemias (Ladines-Castro et al., 2016). Acute leukemia 
transforms rapidly and becomes severe quickly whereas chronic leukemia grows more 
gradually and takes longer to progress (Albrecht 2014; Parikh 2018). Because the disease 
is either myeloid or lymphoid origin and either chronic or acute, the World Health 
Organization recognizes four main groups of leukemias (see Table 1). These 
characteristics of the disease are implemented to designate a patient with either acute 
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Table 1: Leukemia Categorization. Four main types of leukemia and their particular 
attributes (adapted from Rafiq et al., 2018). 
 
Type Cells Involved Cytology Symptoms Statistics 







over 55 years 
of age 




























1.621 Chronic Lymphocytic Leukemia (CLL) 
 Chronic lymphocytic leukemia is a particular type of cancer for which the bone 
marrow produces too many mature lymphocytes. It is one of the most common types of 
leukemia in adults and often appears during or after middle age (Siegel et al., 2015). The 
lymphoproliferative disorder has morphologically mature, but functionally incompetent 
B-cells (Kipps et al., 2017). Clinically, CLL is asymptomatic, as the signs of the disease 
develop slowly in the course of several years (Hus & Roliński, 2015). Unlike other 
leukemias, the prognostic nature of CLL depends specifically on the stage of the cancer 
(Kipps et al., 2017). Because these cancer cells are mature, they travel with the normal 
lymphocytes to the lymph nodes, liver, and spleen (Schwartz & Shamsuddin, 1981). Over 
time these organ systems swell due to the accumulation of these cells (Hus & Roliński, 
2015). There is a genetic component to the disease and risk factors include certain 
hazardous chemicals (Brown 2008). Immunophenotyping and flow cytometry are used to 
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confirm the diagnosis of CLL (Parikh 2018). There is unfortunately no cure for this 
leukemia, but because of the slow progression of the disease, it is not immediately life 
threatening (Dighiero & Hamblin, 2008; Parikh 2018).  
1.622 Acute Lymphocytic Leukemia (ALL)  
 Acute lymphocytic leukemia is the result of mutations in precursor T and B blood 
cells usually due to a chromosomal translocation or abnormal chromosome number 
(Terwilliger & Abdul-Hay, 2017). These genetic circumstances generate atypical cellular 
proteins which regulate cell division. ALL is the most common leukemia overall and the 
most common cancer in children (Smith et al., 2010). Risk factors of the disease include 
antineoplastic agents, ionizing radiation, and Down syndrome (Belson et al., 2007). 
There is a bimodal distribution of those presenting with ALL as the median age of onset 
is 35 years with a large peak at 4-5 years of age and a smaller gradual increase in the 
elderly (Terwilliger & Abdul-Hay, 2017). The prognosis of the disease in children is 
favorable (>90%) while meager in adults (Smith et al., 2010). Because of the rapid nature 
of the disease, ALL – unlike CLL – is fatal if left untreated for even a few weeks or 
months. Fortunately, treatment of ALL is curable depending on the prognostic factors of 
the individual (Terwilliger & Abdul-Hay, 2017).  
1.623 Chronic Myeloid Leukemia (CML)   
 Chronic myelogenous leukemia is a cancer of all of the differentiated white blood 
cells except the lymphocytes (Granatowicz et al., 2015). Because of the nature of a 
chronic leukemia, it is a monoclonal disorder of late – small, mature, but dysfunctional – 
hematopoietic stem cells. The onset of CML is insidious and patients are typically older, 
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with a median age of 40-50 years (Huang et al., 2012). Karyotype analysis of the disease 
presents with a balanced reciprocal translocation of the proto-oncogene ABL with a break 
cluster region resulting in a characteristic change known as the Philadelphia chromosome 
(Serra et al., 2014). It results in the bone marrow assembling protein, called tyrosine 
kinase, that triggers too many hematopoietic stem cells to become white blood cells 
(Granatowicz et al., 2015). Therefore, current treatment of the disease is with a tyrosine 
kinase inhibitor which has led to drastically improved survival rates (Huang et al., 2012; 
Pophali & Patnaik, 2016). Individuals with an early phase of the disease can expect a 
normal life expectancy with Imatinib treatment (Kim et al. 2011).  
1.624 Acute Myeloid Leukemia (AML)  
 Acute myeloid leukemia is a cancer of the myeloid lineage characterized by 
uncontrolled, rapid growth of partially developed white blood cells that build up in the 
bone marrow (Lin & Smith, 2011). Risk factors of AML include antineoplastic agents, 
ionizing radiation, and benzene exposure (Tsai et al., 2014). AML has several different 
subtypes for which prognosis and treatments may vary. Diagnosis of the disease is based 
on morphologic investigation, cytogenetic studies, molecular markers, and cytochemical 
analysis (Lin & Smith, 2011). Death occurs within weeks to months unless a first 
remission is achieved (Foster et al., 2015). 




Figure 4: Statistics on Leukemias. The 2019 estimated cases and deaths from the four 
largest subtypes of leukemias. Acute myeloid leukemia has the worst prognosis with the 
most fatalities. (Adapted from Shallis et al., 2019) 
 
  
ACUTE MYELOID LEUKEMIA  
1.7 Prognostic Challenges  
 Modern knowledge of acute myeloid leukemia has only amplified the sense of 
medical helplessness of the disease because until 2017 previous treatment has not 
improved prognosis. This cancer has been studied in exquisite detail, but without any 
therapeutic or practical advances until recently (Watts & Nimer, 2018). Whole genome 
sequencing has allowed researchers to detect mutation frequency in cancer. However, the 
relationship between potential driver mutations and epigenetic phenotypes in AML 
patients are not yet clear (Li et al., 2016). Furthermore, defining nearly all coding 
mutations in AML at initial presentation has not solved risk assessment of the disease 
(Moarii & Papaemmanuil, 2017). The evaluation of this cancer must involve several 
confounding variables as subclones of any individual with AML have unique functional 
and morphologic properties (Spencer et al. 2014). 
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 Although AML is a relatively rare cancer in the general population, it accounts for 
90% of leukemias in all adults and has the poorest modeling of all of the leukemias 
(Jemal et al., 2002). The cytogenetic and molecular characterization of the disease are 
complex and not well defined (Spencer et al., 2014). There are several dimensions of 
AML which may explain its imperfect risk assessment at initial presentation. The 
mutational and clonal intricacy along with its variable evolution over time have given the 
cancer many paths to resistance from standard chemotherapy (Martignoles et al., 2018). 
More recent investigations of AML have suggested that epigenetic signatures of the 
cancer might play the biggest role in the disease pathogenesis of many AML patients 
(O’Brien et al., 2014).  
The prognosis of AML is starkly different than other forms of leukemia. The fast 
nature and target population of AML reflects its clinical importance (Ley et al., 2010). 
Chronic leukemias may require no treatment due to the late and slow onset of the disease 
(Hus & Roliński, 2015). Although untreated acute leukemias are devastating, there are 
positive therapeutics to slow down the disease if it is of a lymphoid origin and the 
individual is young of age (Terwilliger & Abdul-Hay, 2017). However, AML is an age 
associated cancer with an overall 5 year survival rate of less than 5% in patients over 65 
years of age (Almeida & Ramos, 2016). Because of these statistics, coupled with the slow 
therapeutic advances and challenges, there has recently been a resurgence in the 
awareness and investigative passion of the disease within the healthcare community.  
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1.72 Epidemiology of Acute Myeloid Leukemia   
1.721 Incidence  
The Surveillance, Epidemiology, and End Results (SEER) program of the 
National Cancer Institute (NCI) gathers and publishes information on cancer statistics. It 
is one of the largest cancer registrars covering approximately 34.6% of the United States 
population. The initial SEER reported that age-adjusted AML incidence within the U.S. 
alone ranges from three to five cases per 100,000 population. In addition, the disease is 
the most common acute leukemia in adults despite representing 1.2% of all new cancer 
cases (Maksimovic et al., 2018). The lifetime risk of developing AML is approximately 
0.5% according to the SEER 9 database. Moreover, an estimated 61,048 people are living 
with acute myeloid leukemia in the United States (Data from SEER 9). Notably, the 
incidence rate per 100,000 has been slightly rising in the United States due to a global 
aging population (see Figure 5) (Shallis et al., 2019). The age-adjusted prevalence rates 
in the United Kingdom, Canada, Australia, Sweden, as well as Denmark parallel those of 
the US population suggesting that a model for the pathogenesis of the disease is based on 
a group of fixed variables (Shallis et al., 2019).  
 




Figure 5: The Incidence of AML. The occurrence of the disease in the United States has 
been slightly rising since 1975 but not every year. The overall general increase of AML 
patients is probably due to an aging US population. (Adapted from Shallis et al., 2019) 
 
1.722 Age  
 Acute myeloid leukemia is primarily a disease of age (Almeida & Ramos, 2016). 
While the disease is diagnosed at any age, it is uncommon in those under 45 years of age. 
The incidence of those aged 65 years or older is 20.1 per 100,000 while 2.0 per 100,000 
for those that are younger (SEER Cancer Statistics Review 1975-2016). The median age 
of initial diagnoses is 68 years of age in the United States (see Figure 6) (SEER Database 
2001-2013). Because of the late onset of the cancer, many patients are unable to obtain 
the standard intensive therapies due to other co-existing medical conditions (Maher et al., 
2013). Worse, the disease itself tends to act more aggressively the further one ages due to 
separate comorbidities (López-Otín et al., 2013). These factors have confronted 
healthcare professionals with the age-related challenges of AML.   




Figure 6: Incidence of AML Increases with Advanced Age. The median age in the 
United States is 68 at diagnosis (Adapted from Shallis et al., 2019).  
 
1.723 Gender and Race/Ethnicity  
 Acute myeloid leukemia occurs in all racial groups (Kannan et al., 2014). Males 
across all ethnicities are 1.2-1.6 times more likely to develop AML during their lifetime 
according to the SEER data. Studies in the US, UK, and Canada have an age adjusted 
incidence of 5.42 and 3.47 per 100,000 individuals in males and females respectively 
(Shallis et al., 2019). Native Americans have the highest incidence rate while Caucasians 
have the lowest (Shallis et al., 2019). The exact mechanism accounting for these 
disparities is unclear but suggests a hormonal and social factor might play a role in the 
acquisition of the disease and its pathogenesis (Poynter et al., 2013). Because of the 
challenges in establishing the true prevalence of the disease, many studies consider race a 
confounding variable in AML (Kannan et al., 2014).  
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1.73 Diagnosis and Risk Classification 
 The diagnosis of AML is often tricky and not standardized as individuals present 
initially with unspecific symptoms such as fatigue, chronic inflammation, and muscle 
weakness (Albrecht 2014). Evaluation and initial workup of someone suspected of acute 
myeloid leukemia involves a comprehensive medical history with a physical checkup 
followed by a routine blood sample (Béné et al., 2015). The initial diagnosis of leukemia 
is often quick via a blood smear, but further classification of the cancer requires a bone 
marrow aspiration and biopsy with cytogenetic analysis (Béné et al., 2015). These tests 
are employed to identify specific genes, proteins, and other factors such as translocations 
involved in the cancer. DNA sequencing and cytogenetics are used to classify the AML 
subtype which will guide prognosis and treatment (Grimwade et al., 2010).  
1.74 Morphologic Classification  
Morphology of AML is determined by the identification of the leukemic cell line 
and its stage in differentiation (Ladines-Castro et al., 2016). The mechanism to assess this 
is through the peripheral blood, bone marrow, and less commonly in solid tissues 
(Luciano & Brewster, 2014; Ebert & Hagspiel, 2012). Myeloid blast cells appear small to 
medium in size with high nucleo:cytoplasm (n:c) ratio and dispersed chromatin (Ladines-
Castro et al., 2016). Distinct from other acute leukemias, Auer rods (see Figure 7) present 
themselves in AML, which is a defining hallmark of the cancer (Willis et al., 2005; Bain 
2011). In addition, the histological presentation of the disease further includes increased 
bone marrow cellularity, consisting primarily of granulocytic or monocytic forms and 
variable numbers of erythroid precursors (Orazi 2007). Immunophenotyping can also 
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supplement the diagnosis of specific genetic categories of acute myeloid leukemia (Klco 
et al., 2014). 
 
Figure 7: White Blood Cell Differential. The medical laboratory test provides 
information about the types and amounts of white blood cells. Someone with acute 
myeloid leukemia will typically have a blood smear containing an Auer body (arrow) – a 
hallmark of the disease. An Auer body is an azurophilic needle shaped granule observed 
in myeloid blast cells. (Adapted from Bain 2011)  
 
1.75 Cytogenetic Abnormalities and Pathogenesis 
 Cytogenetic analysis of AML has been studied to analyze the molecular 
pathogenesis of the disease. Recurrent chromosomal structural variations in AML 
individuals have established diagnostic and prognostic markers (Welch et al., 2012). 
However, defining all of the mutations of the disease has not improved its risk 
assessment (Ley et al., 2010). Moreover, approximately 50% of AML patients have a 
normal karyotype that lack structural abnormalities and no driver mutations in any of the 
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recognized driver genes of the disease (Akagi et al., 2009). Interestingly AML genomes 
have the fewest mutations of all adult cancer types with only 23 significantly mutated 
genes (see Figure 8) when corrected for genome size (Marchesi 2013). The most affected 
recurrent genes include FLT3, NPM1, and DNMT3A because they tend to cooccur 
(Wang et al., 2017). Because of the complexity of the disease, there are several 
confounding variables and dimensions of AML (Ley et al., 2010).  
 The AML genomes to date are clonally complex with no exception. They all 
consist of a founding clone with different multigenerational daughter subclones 
(Martignoles et al., 2018). Hematopoietic stem cells divide once a month and develop 
one mutation for each division (Kovtonyuk et al., 2019). Therefore, as an individual ages, 
each progenitor stem cell has a genetic signature with a unique characteristic pattern of 
gene expression. Preleukemic mutations develop over time and slightly skew clonal 
mutations to a founding clone that favor cancer such as abnormalities in FLT3, NPM1, 
and DNMT3A genes (see Figure 8) (Martignoles et al., 2018). The biggest problem with 
the founding clone is that it experiments with additional, upstream mutations to produce 
more subclones for which there are many in an individual with AML (Klco et al., 2014). 
These mechanisms have the potential to explain the explosive, accelerative nature of the 
disease.  
 




Figure 8: The Big Three Genes: FLT3, NPM1 & DNMT3A. There are 23 notable 
mutated genes in acute myeloid leukemia when corrected for gene size. These genes tend 
to cooccur in individuals with AML. In the total distribution, there were 260 recurrently 
mutated genes and 1627 singletons found in the cohort. (Adapted from Ley et al., 2013)  
 
There has been only one robustly correlated gene linked to AML and it is the 
DNMT3A R882 gene (which encodes DNA methyltransferase A) (Ketkar et al., 2020). 
The presence of this defected gene independent of FLT3 or NPM1 mutations has been 
associated with a worse outcome in those individuals with AML as it has an important 
role in chemoresistance (Guryanova et al., 2016). It is believed that the abnormal 
DNMT3A R882 gene is the first in a series of mutations representing the founding clone 
of the cancer. However, the relationship between DNMT3A and AML is unclear as these 
mutations do not cause genomic instability nor change 5-methylcytosine content (Ley et 
al., 2010). Tien et al. (2014) in a sample of 500 AML patients identified DNMT3A 
mutations in 14% of them while 22.9% had a normal karyotype. The presence of this 
very specific mutation may provide a new tool to assess the pathogenesis of AML, but is 
not a causal factor in the development of the cancer (Ley et al., 2010). However, a 
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precise characterization of clonal architecture in AML has important clinical 
implications.   
1.76 Initiating Mutation and Clonal Skewing  
 The initiating mutations of AML have been extensively covered in the literature 
as the disease is clonally complex (Martignoles et al., 2018). There is on average one 
mutation per cell division of hematopoietic stem cells, which engender different types of 
blood cells in lines called myeloid or lymphoid (Kovtonyuk et al., 2019). Because these 
hematopoietic stem cells are long-lived for several decades and divide once a month, 
each hemopoietic stem cell over time has an accumulation of mutations along with their 
own unique genetic signature (O’Brien et al., 2014). Each of these mutations separately 
are considered insignificant, but some produce a preleukemic advantage (Ley et al., 
2010). Certain hematopoietic stem cells are able to then divide quicker. Research has 
shown that these mutations are typically in the FLT3, NPM1, TET2, and DNMT3A 
genes. These initiating mutations in AML tend to skew clonal hemopoiesis in elderly 
patients to a single clone (Ley et al., 2010). Expressed in a different way, individuals 
with AML or clonal hematopoiesis tend to have the same mutations, thus anchoring these 
concepts together (see Figure 9) (Xie et al., 2014). However, the data only represents a 
correlation and not a causation. 
 




Figure 9: Clonal Skewing with AML Initiating Mutations. The amount of mutations in 
6 cancer associated genes increase exponentially with age. These are recurrent mutations 
that are tend to cooccur and coexist. However, cooperation of these genes remains 
unclear. (Adapted from Xie et al., 2014) 
 
 The initiation of acute myeloid leukemia probably begins with a DNMT3A 
mutation followed by a NPM1 and FLT3 mutation (Ley et al., 2010). Subclones then 
exponentially expand after the acquisition of all of the mutations, thus defining the 
explosive nature of the disease. These leukemic cells have been desensitized to the 
massive proliferative signal and are clustered together (Ley et al., 2010). Subclones of 
AML are extremely important due to the hierarchy of the disease (Bonnet & Dick, 1997). 
Moreover, subclones have distinctive functional and morphologic properties such as 
altered growth properties in vitro as well as unique immunophenotypes (Klco et al., 
2014). NPM1 and FLT3 inhibitors are incapable of effectively treating those with AML 
because the founding close still is unaffected and able to more produce more subclones 
(Ley et al., 2010). Therefore, relapse is likely to occur. Hence, current research suggests 
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targeting the founding clone, which may begin with the DNMT3A mutation (see Figure 
10) (Walter et al., 2013; Welch et al., 2012).  
 
 
Figure 10: Clonal Diversity of AML. Variant Allele Frequency (VAF) vs read depth of 
8 AML genomes. Founding clones produce variable subclones. The histogram above 
each scatter plot show clustered VAFs using a Bayesian approach. Higher amplitude 
peaks on the histograms represent an initial DNMT3A mutation in the founding clone 
while the smaller amplitude peaks represent additional, but later mutations in either 
IDH1, FLT3, or both for the subclones. (Adapted from Walter et al., 2013). 
 
1.77 Treatment  
 The main treatment for AML is cytotoxic chemotherapy, but it is sometimes 
combined with targeted drug therapy (Lai et al., 2019). Standard of care is branched into 
two phases: induction of remission and consolidation therapy. The objective of induction 
therapy is to decrease the tumor burden to an undetectable level with traditional 
chemotherapeutic agents (Lai et al., 2019). The standard chemotherapy medication to 
treat AML is cytarabine, which is a pyrimidine nucleoside analog that inhibits the 
synthesis of DNA (Lee et al., 2000). Cytarabine is given intravenously in a single dose 
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for seven straight days then followed by daunorubicin or idarubicin (anthracycline drugs) 
for another three days. This is sometimes called the “7+3” regimen (cytarabine 7 days + 
daunorubicin or idarubicin 3 days) (Lichtman 2013). These drugs are highly effective and 
frequently result in complete remission of leukemia – meaning no visible AML cells are 
seen in the blood or bone marrow when examined under a microscope (Lai et al., 2019). 
However, these tumor-free remissions are temporary because leukemic cells begin to 
regrow afterwards and become better equipped to evade these chemotherapeutic 
medications (Lee et al., 2000). 
 Post remission therapy immediately follows induction treatment. The standard of 
care is usually another dosage of cytarabine or either a stem cell transplant depending on 
the current risk assessment (Lai et al., 2019). Nonetheless, relapse is likely to occur 
within one to two years after starting the initial treatment (Lee et al., 2000). There are 
currently several experimental immunotherapies to target AML for post remission 
therapy. The main treatment is via allogenic stem cell transplantation from a healthy 
donor (Peccatori & Ciceri, 2010). However, the risk of side-effects are life-threatening 
due to the complication of graft vs host disease. Fortunately, there has been an explosion 
of new FDA-approved medications (see Figure 11) that can potentially target acute 
myeloid leukemia (Winer & Stone, 2019).  
The past several decades have seen little improvement in the treatment of AML 
(Lai et al., 2019; Cai & Levine, 2019). Chemotherapeutic agents such as cytarabine and 
daunorubicin are still the standard of care (Lee et al., 2010). These medications were first 
described in 1975 and have been used continuously since 1981. A complete remission 
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rate with the “7+3” treatment is 60-85% for those younger than 60 and a meager 40-60% 
for those older than 60 years of age with AML (Rai et al., 1981). The reason for the lack 
of advancement and outcome with respect to AML treatment for over 40 years stems 
from an incomplete screening mechanism for new leukemic genes (Ley et al., 2010). 
Moreover, healthcare professionals have not successfully targeted the initial mutation(s) 
that potentially engender acute myeloid leukemia. Fortunately, the emerging field of 
epigenetics may hint at a new direction to better understand the complexities of AML, 
resulting in better therapeutic invention (Goldman et al., 2019).  
 
Figure 11. Recent FDA Approvals for AML. There is great activity in the field of AML 
as 8 new drugs have been approved to target new or relapse subtypes of the disease. 
(Adapted from Leukemia & Lymphoma Society of Canada: Acute Myeloid Leukemia – 
Diagnosis and Treatment in 2020) 
 





 The purpose of the thesis is to better characterize the DNMT3A gene as an 
epigenetic driver in clonal hematopoiesis and acute myeloid leukemia. In order to address 
























3.1 Overview  
The goal of the research was to generate DNMT3A proteins for future research 
via a bacterial expression vector. A wild type (WT) and mutated version (W306C) of the 
DNMT3A cDNA were amplified via multiple polymerase chain reactions. In order to 
produce the proteins of interest, versions of the DNMT3A cDNA were ligated into a 
pGEX expression vector. E. coli bacteria were then transformed with the expression 
vector and with the cell’s machinery produced the DNMT3A protein encoded by the 
DNMT3A cDNA. The expression vector encodes an antibiotic resistance cassette to 
choose the colonies that have incorporated the DNMT3A cDNA. The strategy of 
generating the DNMT3A gene’s targeted protein via an expression vector is outlined 
below.  
3.2. Obtain the DNMT3A Sequence  
 Polymerase Chain Reaction (PCR) was the method of amplifying cDNA. The 
process is used very quickly and efficiently produces millions of copies of a single 
segment of cDNA. The ingredients of a successful PCR reaction include (1) the target 
DNA molecule (DNMT3A), (2) the pair of DNA primers, (3) heat-resistant DNA 
polymerase, and (4) deoxyribonucleotide triphosphates (dNTP’s). There was a total of 
four reactions – two templates (WT and W306C DNMT3A) and two primer pairs (F1/R 
and F2/R). The double strands of DNA were heated at 95° C, breaking the electrostatic 
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hydrogen bonds holding them together. Then the PCR solution was cooled to 55° C, 
allowing hybridization to reoccur. The temperature was afterwards increased to an 
optimal 72° C, where the DNA polymerase was able to add the dNTPs to elongate the 
strand in the 5’ to 3’ direction.  
 
Figure 12: PCR Primer Design and Amplification of DNMT3A PWWP Domain. Two 
forward primers were designed as the GC content at 5’ of PWWP domain is high, which 
is potentially difficult to amplify. F1/R amplifies DNMT3A residues 286-420 while F2/R 
amplifies DNMT3A residues 288-420. BamH1-F and XhoI-R primers were chosen in 
order to replicate a specific cDNA sequence of the DNMT3A mRNA that can be 
incorporated into a bacterial expression vector after BamH1 and XhoI digestion.  
 
3.3. Ligating cDNA into the pGEX vector 
 The PCR products were incorporated into a bacterial vector via restriction 
digestion (BamHI and XhoI). These type II restriction endonucleases cut the pGEX 
plasmid at specific locations, facilitating the introduction of the cDNA fragments into the 











Figure 13: Cloning GST-PWWP of DNMT3A. In-frame cloning of the cDNA within 
the BamH1 and Xhol site. The vector consists of an insert and a larger sequence known 
as the backbone.  
 
3.4 Screening  
 The DNMT3A cDNA (WT and 306A) were ligated to the pGEX vector and 
transformed into E. coli bacteria. These recombinant DNA vectors were able to replicate 
in an incubator. There were LB agar plates with AMP for either the DNMT3A WT pGEX 
vector, DNMT3A 306A pGEX vector, or pGEX backbone. These transformed bacteria 
were plated on LB+AMP plates rather than LB plates. The antibiotic used was designed 















 The major goal of the experiment was to generate DNMT3A proteins for future 
research via a bacterial expression vector. There is extensive literature to suggest that 
DNMT3A protein misfolding is associated with hematological malignancies specifically 
with acute myeloid leukemia in the elderly (Ley et al., 2010). Past research on the 
DNMT3A gene has not changed the prognosis of those suffering from leukemia because 
the clonal nature of the disease is complex (Spencer et al. 2014). A wild type (WT) and 
mutant cDNA version of DNMT3A were amplified via PCR. The fragment sizes of the 
cDNA fragments were measured via agarose gel electrophoresis (see Figures 14 & 15). 
The cDNA fragments (WT and W306C DNMT3A cDNA) were not successfully 
integrated into the pGEX bacterial expression vector. Moreover, purified DNMT3A 
proteins were not synthesized, but this is still an ongoing process. Millions of colonies 
were observed on the backbone plate (see Figure 17) thereby confirming a mistake in the 










Figure 14: WT DNMT3A cDNA Agarose Gel Electrophoresis. Following PCR of WT 
DNMT3A cDNA, the fragments were separated based on size. The first column had 
Invitrogen 100 bp DNA Ladder which was used to size the number of base pairs of WT 
DNMT3A cDNA. Approximately 13 individual chromatography-purified DNA 
fragments were represented in the 100 bp DNA Ladder. The fragment length of WT 
DNMT3A cDNA with primers DNMT3A-pwwp-BamH1-F2 and DNMT3A-pwwp-Xhol-
R was 400 base pairs (bp). A loading dye was placed in lane two to visually track DNA 
migration during electrophoresis.  
 
 
Figure 15: W306C DNMT3A cDNA Agarose Gel Electrophoresis. W306C DNMT3A 
cDNA fragments were separated based on size and compared to the Invitrogen 100 bp 
DNA Ladder reference. The fragment length of W306C DNMT3A cDNA with primers 
DNMT3A-pwwp-BamHI-F2 and DNMT3A-pwwp-XhoI-R was 420 base pairs (bp). A 
loading dye was placed in lane two to visually track DNA migration during 
electrophoresis. 
 




Figure 16: pGEX-4T-1 Plasmid Agarose Gel Electrophoresis. Type II restriction 
endonucleases (BamHI and Xhol) were supposed to cut the bacterial expression vector 
into separate two pieces. However, two visible bands on the agarose gel represented an 
error in the conduction of the experiment. Although the vector was cut, the fragment of 
DNA between the BamHI and XhoI was not visible as the segment contained few bases. 
Therefore the agarose gel should have had one fragment consisting solely of the 
backbone of the vector. Two bands here represented a mixture of linear DNA (upper 
band) and the uncut supercoiled DNA. Hence, the reaction was incomplete.  
 
 
Figure 17: E. coli Transformation and Selection. There were millions of colonies on 
the three separate plates. The left petri dish contained the pGEX-4T-1 vector with the 
W306C DNMT3A cDNA while the right petri dish had the pGEX-4T-1 vector with the 
WT DNMT3A cDNA. The middle petri dish was used as the control and was not 
supposed to contain any insert. Unfortunately this was not the case as millions of colonies 










 Cancer treatment is one of the fastest growing specialties in modern medicine 
(Krzyszczyk et al., 2018). In-depth studies on cancer have advanced the understanding of 
the disease and have improved the ever-evolving therapeutic options. Nonetheless, 
scientists and researchers still encounter a wide translational gap between this new 
unprecedented knowledge and patient care because of the complex, dynamic nature of 
cancer (Ghoshal 2017). Great genetic diversity is seen in cancer as it is produced by 
competition among clonal lineages generated by somatic mutations (Ley et al., 2010). It 
is widely assumed that the greater the genetic diversity in a tumor, the more likely it will 
progress to malignancy. However, acute myeloid leukemia is a notable exception as it 
possesses relatively few mutations across the genome (Ley et al., 2010). The relative 
paucity of genetic aberrancy in acute myeloid leukemia might be a key critical reason in 
its cytotoxicity and poor prognosis. Therefore, the cure for a particular cancer cannot be 
based solely on its genetics.  
The main challenge in cancer treatment is its clonal evolving nature. Nearly every 
known cancer originates from one ancestral stem cell that has the developed the capacity 
to renew indefinitely (Veith et al., 1987; Feinberg et al., 1985). Hence, there are limitless 
number of descendants with potential unbridled growth. Worse, the generations of each 
cancer lineage are different (Izaguirre et al., 1979). The genetic instability of cancer, 
coupled with its mirthless expansion, provide an almost an omnipotent weapon against 
the immune system and chemotherapeutic drugs. Cancer, as stated by Siddhartha 
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Mukherjee in his Pulitzer Prize winning book The Emperor of All Maladies: A Biography 
of Cancer, is the “ultimate product of Darwinian selection” (p. 51). The fitness of the 
disease evolves and increases after each subsequent generation (Smetana et al., 2019). 
Therefore, the cure of cancer begins with its prevention. 
 The prognosis of AML has been constant for several decades due to the 
complexity of the disease and failure to clear all variants associated with increased risk of 
relapse. Moreover, initiating mutations such as DNMT3A are more persistent and less 
likely to be cleared than cooperating mutations. The reason might stem from epigenomic 
alterations, specifically the DNMT3A R882 mutation that reduces methyltransferase 
activity in AML cells. Moreover, R882H AMLs have altered chromatin structure and 
very few canonical changes in gene expression (Klco et al., 2014). Knowledge regarding 
this specific mutation is in its early stages as it is difficult to detect despite deep DNA 
analysis. Because initiating mutations play an important role in cancer development, 
DNMT3A R882H is a major therapeutic target. New research has suggested that altering 
the WT:R882H heterodimer with a small molecule could potentially restore methylation 
activity and therefore may cure hematological malignancies as well as clonal 
hematopoiesis (Klco et al., 2014).   
 The purpose of this research project was to generate DNMT3A proteins for 
further research as it is an important regulator in clonal hematopoiesis and acute myeloid 
leukemia. Data gathered in the laboratory was incomplete. The primers used to amplify 
the cDNA were successful; however, the bacterial vector was incompletely cut. Hence, 
the control for the experiment - the petri dish that contained only the backbone DNA - 
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produced millions of colonies even on a non-ampicillin plate. Although the experiment is 
an ongoing process, certain steps must be performed again in order to generate the 
DNMT3A proteins of interest with the goal of characterizing them in the future.  
 There is a convergence of topics when discussing acute myeloid leukemia. The 
age-related component of the disease, along with the concept of clonal hematopoiesis, 
have suggested an error in the DNMT3A gene producing a mutant DNMT3A protein. 
Because the elderly population in the United States according to the Census Bureau 
website is estimated to more than double in the next several decades, the impact of a 
mutant DNMT3A gene will continue to rise. Therefore it is critical to restore function in 
this gene for those battling acute myeloid leukemia. In addition, further characterization 
of the DNMT3A gene will have an impact in cancer research, but more importantly 
critical care. A mutation in the DNMT3A gene is usually present in the founding clone of 
AML and therefore proper treatment should focus on this gene mutation rather than 
separate mutations in the subclones (Ley et al., 2013). If healthcare professionals 
successfully target and treat the DNMT3A mutation, the prognosis of acute myeloid 
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